Staphylococcal Enterotoxin B Toxic Shock Syndrome Induced by Community-acquired Methicillin-resistant *Staphylococcus aureus* (CA-MRSA)

Takeru Kashiwada1, Ken Kikuchi2, Shinji Abe1, Hidehito Kato3, Hiroki Hayashi1, Taisuke Morimoto1, Koichi Kamio1, Jiro Usuki1, Shinniro Takeda4, Keiji Tanaka4, Ken’ichi Imanishi3, Junji Yagi3, Arata Azuma1 and Akihiko Gemma1

Abstract

We herein report a case of toxic shock syndrome (TSS) associated with the 2009 pandemic H1N1 (pH1N1) influenza virus and a community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA) infection in a 16-year-old Vietnamese girl. Staphylococcal enterotoxin B (SEB) was detected in the patient’s serum, and the level of anti-SEB antibodies was found to be elevated. A flow cytometric analysis showed evidence of activated SEB-reactive V\(\beta\)3+ and V\(\beta\)12+ T cells. These data suggest that the CA-MRSA-induced activation of SEB-reactive T cells may cause TSS in patients with pH1N1 virus infection. Moreover, this is the first report describing immunological confirmation of SEB contributing directly to TSS in a patient fulfilling the diagnostic criteria of TSS.

Key words: toxic shock syndrome, staphylococcal enterotoxin B, T-cell antigen receptor, methicillin resistant *Staphylococcus aureus*, swine-origin influenza A H1N1 virus

(Intern Med 51: 3085-3088, 2012)  
(DOI: 10.2169/internalmedicine.51.7295)

Introduction

*Staphylococcus aureus* can produce many enterotoxins, including toxic shock syndrome toxin-1 (TSST-1) or staphylococcal enterotoxin B (SEB), that can cause toxic shock syndrome (TSS) (1, 2). Some researchers have reported increased levels of anti-SEB immunoglobulins in patients diagnosed with TSS (2). The massive proliferation of T cells bearing specific V\(\beta\) elements in their antigen receptors leads to the overproduction and/or release of cytokines, thus causing clinical TSS symptoms such as fever, hypotension and shock. Although the clinical definition of TSS is well established, there are few reports describing immunological confirmation of the direct contribution of TSST-1 or other staphylococcal superantigens to TSS (3). To our knowledge, the present report is the first confirming the activation of SEB-reactive V\(\beta\)3+ and V\(\beta\)12+ T cells in a patient fulfilling the diagnostic criteria of TSS. Moreover, the present case of TSS was associated with community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA) and swine-origin influenza A H1N1 viral infection. Our observations support the hypothesis that the presence of CA-MRSA may result in high mortality in patients with pandemic H1N1 influenza (pH1N1) viral infections.

Case Report

We previously reported the case of a 16-year-old Vietnamese patient with a 2009 pH1N1 virus infection (4). The 16-year-old girl with no medical history developed fever, general fatigue and diarrhea. Type-A influenza was diag-
antibiotic treatment, the patient’s general condition gradually demonstrated bilateral necrotizing pneumonia. After changing the mography of the chest obtained on Day 9 (Figure) demonstrated bilateral consolidations with multiple cavity lesions with necrotizing pneumonia.

On arrival, the patient’s temperature was 41.2°C, her blood pressure was 90/40 mmHg, her heart rate was 150 bpm and her respiratory rate was 35 breaths/min. A physical examination showed sunburn-like erythematous maculopapular eruptions on the patient’s chest. Several hours after being admitted, the patient developed respiratory failure that required endotracheal intubation. During the intubation procedure, large amounts of sputum were seen; samples were obtained and sent for culture. The patient was administered a large dose of crystalloid fluid and norepinephrine, oseltamivir and antibiotics (initially ampicillin/sulbactam). Real-time polymerase chain reaction (PCR) revealed a pH1N1 virus infection in samples of nasopharyngeal swabs taken at the time of admission.

On Day 3, the sputum culture obtained upon admission grew MRSA. In addition, the patient’s chest rash had spread to her abdomen. The patient’s symptoms fulfilled the clinical criteria of TSS (1), specifically, fever, rash, desquamation, hypotension and the involvement of at least three organ systems. The antibiotic therapy was changed to linezolid and polymyxin B-immobilized fiber systems. The antibiotic therapy was changed to linezolid and polymyxin B-immobilized fiber systems. The antibiotic therapy was changed to linezolid and polymyxin B-immobilized fiber systems. The antibiotic therapy was changed to linezolid and polymyxin B-immobilized fiber systems.

On Day 9, the chest computed tomography (CT) demonstrated bilateral consolidations with multiple cavity lesions with necrotizing pneumonia.

Peripheral blood samples obtained from the patient on Days 11 and 22 were analyzed using flow cytometry. There was a slightly higher fraction of SEB-reactive T cells (Vβ3+ and Vβ12+), but not SEB-nonreactive T cells (Vβ2+), in the patient’s blood samples compared with control specimens. The CD45RO+ fraction was markedly higher in the SEB-reactive T cells than in the SEB-nonreactive T cells (Table 1). The activation of SEB-reactive T cells decreased on Day 22 when the patient recovered and was discharged from the ICU. The patient’s serum levels of SEB and anti-SEB antibodies were assayed according to previously published methods (7). The serum SEB levels were high at the time of hospitalization and decreased after Day 8. In contrast, the serum anti-SEB IgG and IgM titers increased gradually over three weeks after the patient’s admission to the hospital (Table 2).

Discussion

TSST-1 and SEB have potent stimulatory effects in each specific T-lymphocyte repertoire. An enhanced expression of Vβ2+ T cells has been reported in TSST-1-positive subjects (3), whereas selective stimulation of Vβ3+ and Vβ12+ elements has been demonstrated in SEB-positive subjects (8). Matsuda et al. confirmed that TSST-1-reactive Vβ2+ CD4+ T cells markedly expanded in nine TSS patients with TSST-1 and that approximately 80% of the Vβ2+ CD4+ T cells were CD45RO+ at the peak of expansion (3). In that study, the levels of the CD45RO+ fraction then decreased to control levels (∼40-50%) over the course of four to seven weeks. In the present study, we detected noticeably higher levels of the CD45RO+ fraction in the SEB-reactive T cells (Vβ3+ and Vβ12+) than in the SEB-nonreactive T cells (Vβ2+). These results suggest that SEB-reactive T cells, but not SEB-nonreactive T cells, were significantly activated in
the present patient and indicate that this case of TSS was induced by SEB. In addition, we confirmed high serum SEB levels at the time of hospitalization. Furthermore, after the serum SEB levels started to decrease, we noted a gradual increase in the serum anti-SEB immunoglobulin levels over the following three weeks. These findings support our conclusion that, in this patient, SEB was involved in the manifestation of TSS. Because we cannot entirely exclude perturbation of the immune response by the pH1N1 coinfection in our patient, obtaining further clinical experience supported by laboratory findings is crucial.

TSS is a well-known, potentially serious complication of influenza (1). Cohort studies have revealed that fatal cases of pH1N1 virus infection involved younger patients than those of seasonal influenza (9, 10). Many cases of hypotension or shock have been reported concomitant with pH1N1 virus infection, particularly in children (9). In the present case, the patient presented with shock and severe respiratory failure concomitant with pH1N1 infection and was ultimately diagnosed as having TSS resulting from CA-MRSA. This suggests that many of the reported cases of pH1N1 virus infection with shock were, in fact, TSS associated with CA-MRSA.

It is unclear how CA-MRSA is involved in the clinical course of patients with pH1N1. A fatal adult case of CA-MRSA infection associated with pH1N1 has been reported in Hong Kong (11). In that case, a postmortem histological examination of the lung tissue revealed the presence of both CA-MRSA (SCC mec type IV, multilocus sequence type ST-30) and pH1N1 pneumonia in an immunocompetent 42-year-old patient. The MRSA strain in our patient originated from Taiwan and has been reported to occur in other countries (12). Given the relative ease of movement between populations, the presence of this infection in a Vietnamese patient may well be consistent with bacteria acquired from Taiwan. Several types of CA-MRSA are widespread throughout the regions of East Asia (13). The emergence of pandemic influenza and the prevalence of CA-MRSA in many countries may cause increased morbidity and mortality in infected individuals.

In addition to TSS, we demonstrated the presence of PVL in our patient. CA-MRSA with PVL can cause the necrotizing pneumonia seen in our patient (14). PVL is a significant virulence factor for S. aureus, and it may be possible that SEB-PVL double-positive MRSA has a greater virulence for infected individuals.

The present report is the first of TSS in which activation of SEB-reactive Vβ3+ and Vβ12+ T cells has been confirmed. Moreover, the observations in the present case suggest that the involvement of TSS in pH1N1 infection may be underestimated. TSS induced by CA-MRSA should be considered when patients with influenza present with symptoms of hypotension or skin rash. Publicizing the extent of resistant microbes present in an area and considering CA-MRSA when determining the most appropriate treatment could improve the outcomes of patients with pH1N1.

The authors state that they have no Conflict of Interest (COI).

Table 1. Expansion of Activation Marker in CD4+ T Cells from Toxic Shock Syndrome Patient

<table>
<thead>
<tr>
<th>Time after Admission</th>
<th>Percentage of</th>
<th>Percentage of</th>
<th>Percentage of</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vβ2+ T cells (CD45RO−) fraction*</td>
<td>Vβ3+ T cells (CD45RO−) fraction</td>
<td>Vβ12+ T cells (CD45RO−) fraction</td>
</tr>
<tr>
<td>Day 11</td>
<td>8.5% (34.1)</td>
<td>10.6% (66.0)</td>
<td>3.9% (74.4)</td>
</tr>
<tr>
<td>Day 22</td>
<td>8.4% (38.1)</td>
<td>9.5% (48.4)</td>
<td>3.1% (61.3)</td>
</tr>
</tbody>
</table>

*Percentage of the CD45RO− fraction among the Vβ2+ CD4+, Vβ3+ CD4+, or Vβ12+ CD4+ T cells. Mean percentage and standard deviation of Vβ2+, Vβ3+ or Vβ12+ T cells in CD4+ T cells from normal specimens; Vβ2+ (9.4 ± 1.4), Vβ3+ (4.4 ± 2.3), and Vβ12+ (1.8 ± 0.4)

Table 2. SEB Levels and Anti-SEB IgG and IgM Titers in Serum after Admission

<table>
<thead>
<tr>
<th>Test</th>
<th>Day1</th>
<th>Day3</th>
<th>Day 8</th>
<th>Day 22</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEB (pg/mL)</td>
<td>149</td>
<td>&lt;50</td>
<td>&lt;50</td>
<td>&lt;50</td>
</tr>
<tr>
<td>Anti-SEB IgG</td>
<td>0.005</td>
<td>0.173</td>
<td>0.114</td>
<td>0.649</td>
</tr>
<tr>
<td>Anti-SEB IgM</td>
<td>0.08</td>
<td>0.069</td>
<td>0.079</td>
<td>0.255</td>
</tr>
</tbody>
</table>

*SEB; Cutoff concentration at 50 pg/mL (less than 1% false-positive) Titer of anti-SEB (IgG and IgM) were measured by ELISA. The antibody titers were determined based on the OD at 450 nm. Data are shown as OD. SEB; staphylococcal enterotoxin B, Ig; immunoglobulin, ELISA; enzyme-linked immunosorbent assay; OD; optical density
Acknowledgement
The authors thank Naoko Shibayama of TORAY Medical for measuring the SEB titers and antibodies.

References